

12-21-01

RECEIVED

DEC 27 2001

TECH CENTER 600/2900

Please type a plus sign (+) inside this box → ☐Approved for use through 09/30/2001 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/284,858
	Filing Date	April 21, 1999
	First Named Inventor	Isaac Ghebre-Sellassie
	Group Art Unit	1617
	Examiner Name	E. Webman
Total Number of Pages in This Submission	Attorney Docket Number	5741-01-CA

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) <div style="border: 1px solid black; padding: 2px; margin-top: 5px;">Associate Power of Attorney Certificate of Express Mail</div>
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	James Proscia
Signature	<i>James Proscia</i>
Date	12/17/01

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:			
Typed or printed name	Beth N. Gaines		
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PD-5741-01-CA

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : ISAAC GHEBRE-SELLASSIE

EXAMINER : E. WEBB

SERIAL NO : 09/284,858

ART UNIT : 1617

FILED : APRIL 21, 1999

PAPER NO : 13

FOR : SOLID PHARMACEUTICAL DOSAGE FORMS IN FORM OF A PARTICULATE DISPERSION

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

#14/D
AKD
1-12-02

AMENDMENT AND REMARKS

December 17, 2001

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is a response to the Office Action issued in the captioned application on August 15, 2001, Paper No. 12. A one-month extension of time accompanies this paper.

REMARKS

Reconsideration of the above-captioned application in light following remarks is respectfully requested. Claims 1-7 and 10-20 are pending in the application. Claims 11-20 are withdrawn from consideration. Claims 1-7 and 10 are rejected.

Claims 1, 5-7 and 10 stand rejected under 35 U.S.C. 102 (b) as allegedly being anticipated by Tanaka et al. Applicant respectfully traverses the rejection and submits that the invention embraced by Claims 1-7 and 10 are not anticipated under 35 U.S.C. 102(b) for the reasons set forth below.

The present invention claims a pharmaceutical dosage form that provides for the enhanced release of sparingly water-soluble compounds. The claimed invention is a solid particulate pharmaceutical dosage form suitable for oral delivery comprising a sparingly water-soluble particulate pharmaceutical agent in crystalline particulate form, wherein said particulate